Deutsche Bank today maintained a Buy rating on Biogen (NASDAQ: BIIB) and raises its price target to $240.00 (from $170.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE